These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 38981743)

  • 1. Mammalian cell expressed recombinant trimeric spike protein is a potent vaccine antigen and confers near-complete protection against SARS-CoV-2 infection in Hamster.
    Jitender ; Vikram Kumar B; Singh S; Verma G; Kumar R; Mishra PM; Kumar S; Nagaraj SK; Nag J; Joy CM; Nikam B; Singh D; Pooja ; Kalidas N; Singh S; Mumtaz ; Bhardwaj AK; Mankotia DS; Ringe RP; Gupta N; Tripathi S; Mishra RPN
    Vaccine; 2024 Aug; 42(20):126099. PubMed ID: 38981743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Corzo C; Noriega MA; Sánchez-Cordón PJ; Labiod N; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2024; 15():1420304. PubMed ID: 39267752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal administration of unadjuvanted SARS-CoV-2 spike antigen boosts antigen-specific immune responses induced by parenteral protein subunit vaccine prime in mice and hamsters.
    Agbayani G; Akache B; Renner TM; Tran A; Stuible M; Dudani R; Harrison BA; Duque D; Bavananthasivam J; Deschatelets L; Hemraz UD; Régnier S; Durocher Y; McCluskie MJ
    Eur J Immunol; 2024 Jun; 54(6):e2350620. PubMed ID: 38561974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.
    Brunet J; Choucha Z; Gransagne M; Tabbal H; Ku M-W; Buchrieser J; Fernandes P; Batalie D; Lopez J; Ma L; Dufour E; Simon E; Hardy D; Petres S; Guinet F; Strick-Marchand H; Monot M; Charneau P; Majlessi L; Duprex WP; Gerke C; Martin A; Escriou N
    J Virol; 2024 May; 98(5):e0169323. PubMed ID: 38563763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters.
    Lu M; Zhang Y; Dravid P; Li A; Zeng C; Kc M; Trivedi S; Sharma H; Chaiwatpongsakorn S; Zani A; Kenney A; Cai C; Ye C; Liang X; Qiu J; Martinez-Sobrido L; Yount JS; Boyaka PN; Liu SL; Peeples ME; Kapoor A; Li J
    J Virol; 2021 Sep; 95(20):e0059221. PubMed ID: 34379509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-administration of recombinant BCG and SARS-CoV-2 proteins leads to robust antiviral immunity.
    Ramírez MA; Loaiza RA; Martínez-Balboa Y; Bruneau N; Ramírez E; González PA; Bueno SM; Kalergis AM
    Vaccine; 2024 Oct; 42(23):126203. PubMed ID: 39178767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters.
    Hsieh M-S; Hsu C-W; Liao H-C; Lin C-L; Chiang C-Y; Chen M-Y; Liu S-J; Liao C-L; Chen H-W
    J Virol; 2024 Feb; 98(2):e0154623. PubMed ID: 38299865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.
    Ying B; Liang C-Y; Desai P; Scheaffer SM; Elbashir SM; Edwards DK; Thackray LB; Diamond MS
    J Virol; 2024 Sep; 98(9):e0057424. PubMed ID: 39194250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity.
    Scaglione A; Opp S; Hurtado A; Lin Z; Pampeno C; Noval MG; Thannickal SA; Stapleford KA; Meruelo D
    Front Immunol; 2021; 12():719077. PubMed ID: 34394127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern.
    Lu M; Chamblee M; Zhang Y; Ye C; Dravid P; Park JG; Mahesh KC; Trivedi S; Murthy S; Sharma H; Cassady C; Chaiwatpongsakorn S; Liang X; Yount JS; Boyaka PN; Peeples ME; Martinez-Sobrido L; Kapoor A; Li J
    Proc Natl Acad Sci U S A; 2022 Aug; 119(35):e2110105119. PubMed ID: 35994646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens.
    Counoupas C; Pino P; Stella AO; Ashley C; Lukeman H; Bhattacharyya ND; Tada T; Anchisi S; Metayer C; Martinis J; Aggarwal A; Dcosta BM; Britton WJ; Kint J; Wurm MJ; Landau NR; Steain M; Turville SG; Wurm FM; David SA; Triccas JA
    Microbiol Spectr; 2022 Feb; 10(1):e0169521. PubMed ID: 35171046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern.
    Renner TM; Akache B; Stuible M; Rohani N; Cepero-Donates Y; Deschatelets L; Dudani R; Harrison BA; Baardsnes J; Koyuturk I; Hill JJ; Hemraz UD; Régnier S; Lenferink AEG; Durocher Y; McCluskie MJ
    Front Immunol; 2023; 14():1182556. PubMed ID: 37122746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
    Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
    Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
    Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J
    J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
    Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2021; 12():824728. PubMed ID: 35154086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19.
    Kuo TY; Lin MY; Coffman RL; Campbell JD; Traquina P; Lin YJ; Liu LT; Cheng J; Wu YC; Wu CC; Tang WH; Huang CG; Tsao KC; Chen C
    Sci Rep; 2020 Nov; 10(1):20085. PubMed ID: 33208827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants.
    Liu H; Zhou C; An J; Song Y; Yu P; Li J; Gu C; Hu D; Jiang Y; Zhang L; Huang C; Zhang C; Yang Y; Zhu Q; Wang D; Liu Y; Miao C; Cao X; Ding L; Zhu Y; Zhu H; Bao L; Zhou L; Yan H; Fan J; Xu J; Hu Z; Xie Y; Liu J; Liu G
    Vaccine; 2021 Nov; 39(48):7001-7011. PubMed ID: 34750014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.
    Jangra S; Landers JJ; Rathnasinghe R; O'Konek JJ; Janczak KW; Cascalho M; Kennedy AA; Tai AW; Baker JR; Schotsaert M; Wong PT
    Front Immunol; 2021; 12():729189. PubMed ID: 34603303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern.
    Garg R; Liu Q; Van Kessel J; Asavajaru A; Uhlemann EM; Joessel M; Hamonic G; Khatooni Z; Kroeker A; Lew J; Scruten E; Pennington P; Deck W; Prysliak T; Nickol M; Apel F; Courant T; Kelvin AA; Van Kessel A; Collin N; Gerdts V; Köster W; Falzarano D; Racine T; Banerjee A
    Vaccine; 2024 Aug; 42(20):125980. PubMed ID: 38769033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.